Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Viking Therapeutics, Inc. (VKTX) had Non-Operating Income/Expense of $4.58M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-128.02M |
|
-- |
|
-- |
|
$132.60M |
|
$-132.60M |
|
|
Non-Operating Income/Expense |
$4.58M |
$-128.02M |
|
$-128.05M |
|
$-128.02M |
|
$-128.02M |
|
$-128.02M |
|
$-128.05M |
|
$-132.60M |
|
$-133.32M |
|
116.26M |
|
116.26M |
|
$-1.10 |
|
$-1.10 |
|
| Balance Sheet Financials | |
$517.56M |
|
-- |
|
$4.33M |
|
$521.90M |
|
$109.66M |
|
-- |
|
$3.92M |
|
$113.58M |
|
$408.32M |
|
$408.32M |
|
$408.32M |
|
116.65M |
|
| Cash Flow Statement Financials | |
$-239.15M |
|
$163.62M |
|
$35.66M |
|
$165.81M |
|
$125.96M |
|
$-39.85M |
|
$21.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-239.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.35% |
|
-31.35% |
|
-24.53% |
|
-31.35% |
|
$3.50 |
|
$-2.06 |
|
$-2.06 |
|